Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms.

导出 OA

翻译打印收藏纠错

第一作者： Hoi Ki Joshua,Tam

第一单位： Ipswich Public Hospital, Queensland Health, Ipswich, QLD, Australia.

作者： Hoi Ki Joshua,Tam ^[1] ; Philip C,Robinson ^[2] ; Peter,Nash ^[3]

作者单位： Ipswich Public Hospital, Queensland Health, Ipswich, QLD, Australia. ^[1] The University of Queensland, Herston, QLD, 4006, Australia.;Department of Rheumatology, Royal Brisbane & Women's Hospital, Herston, QLD, Australia. ^[2] School of Medicine and Dentistry, Griffith University, Gold Coast, QLD, Australia. drpnash@tpg.com.au. ^[3]

关键词 Ankylosing spondylitis Bimekizumab Brodalumab IL-17 Ixekizumab Psoriatic arthritis Secukinumab

主题词细胞因子类(Cytokines);人类(Humans);炎症(Inflammation);白细胞介素17(Interleukin-17);生活质量(Quality of Life);风湿性疾病(Rheumatic Diseases)

DOI 10.1007/s11926-022-01084-4

PMID 35861937

发布时间 2024-09-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交